All In Biotech

Drug Trial Radar · NCT07943598

A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy

A Phase 2 Open-Label Extension Study to Assess the Safety and Efficacy of Brogidirsen in Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 16, 2026

Primary completion

Sep 3, 2029

Study completion Sep 3, 2029

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.

Conditions

  • Duchenne Muscular Dystrophy
  • Exon 44
  • DMD

Interventions

  • BrogidirsenDrug

    Brogidirsen will be administered for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until Brogidirsen is commercially available, whichever is earlier.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Through study completion, an average of 124 weeks
  2. Change in baseline in the following assessments: 12-lead electrocardiograms (ECGs), Vital signs, Physical and neurological examinations, Clinical laboratory testsTime frame: Through study completion, an average of 120 weeks

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Virginia Commonwealth University Health System

    Richmond, Virginia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Fukui Prefectural Hospital

    Fukui-shi, Fukui, Japan

  • NHO Nagara Medical Center

    Nagara, Gifu-shi, Gifu, Japan

  • NHO Osaka Toneyama Medical Center

    Toyonaka, Osaka, Japan

  • Shiga General Hospital

    Moriyama-shi, Shiga, Japan

  • National Center of Neurology and Psychiatry

    Kodaira, Tokyo, Japan

  • Starship Children's Hospital

    Auckland, New Zealand

  • Seoul National University Hospital

    Seoul, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam, South Korea

  • Ankara Bilkent City Hospital

    Ankara, Turkey, Turkey (Türkiye)

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey, Turkey (Türkiye)

  • S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital

    Izmir, Turkey, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.